| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20047807 | HPV | ENSG00000023572.10 | protein_coding | GLRX2 | No | No | 51022 | Q9NS18 |
| TVIS44044055 | HTLV-1 | ENSG00000023572.10 | protein_coding | GLRX2 | No | No | 51022 | Q9NS18 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GLRX2 |
|---|---|
| DrugBank ID | DB00143 |
| Drug Name | Glutathione |
| Target ID | BE0002292 |
| UniProt ID | Q9NS18 |
| Regulation Type | |
| PubMed IDs | 17355958; 17546662; 17401194 |
| Citations | Hashemy SI, Johansson C, Berndt C, Lillig CH, Holmgren A: Oxidation and S-nitrosylation of cysteines in human cytosolic and mitochondrial glutaredoxins: effects on structure and activity. J Biol Chem. 2007 May 11;282(19):14428-36. Epub 2007 Mar 13.@@Sagemark J, Elgan TH, Burglin TR, Johansson C, Holmgren A, Berndt KD: Redox properties and evolution of human glutaredoxins. Proteins. 2007 Sep 1;68(4):879-92.@@Sheng J, Ye J, Rosen BP: Crystallization and preliminary X-ray crystallographic analysis of Escherichia coliglutaredoxin 2 in complex with glutathione and of a cysteine-less variant without glutathione. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Apr 1;63(Pt 4):280-2. Epub 2007 Mar 12. |
| Groups | Approved; Investigational; Nutraceutical |
| Direct Classification | Peptides |
| SMILES | N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O |
| Pathways | Arachidonic Acid Metabolism; Flurbiprofen Action Pathway; 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency; Oxaprozin Action Pathway; Rofecoxib Action Pathway; Pyruvate Kinase Deficiency; Acetaminophen Metabolism Pathway; Mefenamic Acid Action Pathway; Bromfenac Action Pathway; 5-Oxoprolinuria; gamma-Glutamyltransferase Deficiency; Naproxen Action Pathway; Sulindac Action Pathway; Glutathione Synthetase Deficiency; Piroxicam Action Pathway; Nabumetone Action Pathway; 2-Hydroxyglutric Aciduria (D and L Form); Meloxicam Action Pathway; Cyclophosphamide Action Pathway; Succinic Semialdehyde Dehydrogenase Deficiency; Valdecoxib Action Pathway; Ketorolac Action Pathway; 5-Oxoprolinase Deficiency; Acetylsalicylic Acid Action Pathway; Antipyrine Action Pathway; Glutathione Metabolism; Diclofenac Action Pathway; Homocarnosinosis; Cyclophosphamide Metabolism Pathway; Nepafenac Action Pathway |
| PharmGKB | PA449780 |
| ChEMBL | CHEMBL1543 |
